BioLife Solutions shareholders re-elect board, approve executive pay and auditor

BioLife Solutions, Inc. (NASDAQ:BLFS) held its 2025 annual meeting of stockholders on Wednesday. According to a press release statement based on an SEC filing, shareholders re-elected all seven director nominees to the board, approved executive compensation in a non-binding advisory vote, and ratified the appointment of Grant Thornton LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

As of the record date of June 23, 2025, there were 47,835,214 shares of common stock outstanding and entitled to vote. At the meeting, 43,063,037 shares were present or represented by proxy.

The following directors were re-elected to serve until the 2026 annual meeting: Roderick de Greef, Catherine Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, Tony Hunt, and Timothy Moore. For each nominee, votes in favor ranged from 20,731,406 to 40,460,424, with votes withheld ranging from 88,264 to 19,817,282. There were 2,514,349 broker non-votes for each director nominee.

Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. There were 38,403,856 votes for, 2,060,352 against, 84,480 abstentions, and 2,514,349 broker non-votes.

The appointment of Grant Thornton LLP as the independent registered public accounting firm for the current fiscal year was ratified, with 43,024,019 votes for, 11,169 against, and 27,849 abstentions.

All information is based on a press release statement and the company’s SEC filing.

In other recent news, BioLife Solutions reported its second-quarter 2025 financial results, highlighting a revenue of $25.4 million, which marked a 29% increase year-over-year. This revenue figure surpassed the projections of H.C. Wainwright, which had estimated $24.2 million. Despite the revenue success, the company experienced a net loss of $15.8 million, or $0.33 per share, significantly missing the expected loss of $2.0 million. This larger-than-anticipated loss was attributed to a $15.5 million in-process R&D expense related to the PanTHERA transaction. Following these results, H.C. Wainwright raised its price target for BioLife Solutions from $30 to $32, maintaining a Buy rating on the stock. The company’s earnings per share of -$0.33 fell short of the forecasted -$0.03, reflecting challenges in profitability. Despite investor concerns over this earnings miss, BioLife Solutions raised its revenue guidance, indicating confidence in future sales growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.